0.00Open0.00Pre Close0 Volume0 Open Interest2.00Strike Price0.00Turnover0.00%IV-46.52%PremiumOct 18, 2024Expiry Date1.74Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.78Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Savara Stock Discussion
Savara Announces Expanded Access Program (Eap) for Molgramostim Inhalation Solution (Molgramostim) for Patients With Autoimmune Pulmonary Alveolar Proteinosis (Apap)
Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Inc. (Nasdaq: SVRA) has announced the Savara Early Access Program, an Expanded Access Program (EAP) for molgramostim inhalation solution to treat patients with autoimmune pulmonary alveolar proteinosis (aPAP). This program allows physicians to request molgramostim for eligible aPAP patients in select re...
Gapping up
$Boeing (BA.US)$ shares rose by 4.1% in premarket US trading on Monday after the company tentatively agreed to a 25% pay increase for its biggest union, possibly averting a damaging strike.
Crypto-related stocks such as digital coin exchange $Coinbase (COIN.US)$ and crypto miners $CleanSpark (CLSK.US)$ and $MARA Holdings (MARA.US)$ advanced prior to the opening bell, buoyed by Bitcoin's gain, which ex...
📊⚡️📊
Savara Announces New Data from Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Were Presented at the European Respiratory Society (ERS) Congress 2024
Savara Inc. (Nasdaq: SVRA) presented new data from the Phase 3 IMPALA-2 trial of molgramostim for autoimmune Pulmonary Alveolar Proteinosis (aPAP)at the ERS Congress 2024. The trial met its primary endpoint, showing significant i...
1 HOUR AGO, 6:45 AM EDT
VIA BUSINESSWIRE
Mean Change From Baseline in Disease Severity Score (DSS) Showed Significant Improvement with Molgramostim Compared with Placebo at Wee...
Savara to Present New Data From Pivotal Phase 3 Impala-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (Apap) at the European Respiratory Society (Ers) Congress 2024 September 7th thru 11th
No comment yet